Bryologyx
Founded 2016
About Bryologyx
BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability of cancer immunotherapies. The company is capitalizing on two recent scientific advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their availability for commercial development.
Company Facts
- Founded: 2016
- Legal name: BryoLogyx Inc.
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Website: bryologyx.com
- Phone: [email protected]
Social Profiles
Canonical: https://fsome.com/organization/bryologyx-8400948 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.